Ortho Clinical Diagnostics (OCDX) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.19 per share a year ago.

Ortho Clinical Diagnostics (OCDX) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.26 per share a year ago.

RARITAN, N.J., April 26, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, has been recognized with a ...

RARITAN, N.J.--(BUSINESS WIRE)--Ortho Clinical Diagnostics today announced the appointments of accomplished industry veterans Carl Hull, Ron Labrum, Thomas Mac Mahon and José (Joe) E. Almeida as ...

Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 ...

RARITAN, N.J., May 3, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced the availability of enhanced ...

Aligned with its mission to improve and save lives with diagnostics, Ortho Clinical Diagnostics today announced it is launching to market its SARS-CoV-2 (COVID-19/coronavirus) antibody test—the VITROS ...

(Reuters) - Private equity firm Carlyle Group LP (CG.O) is exploring a sale or initial public offering of Ortho-Clinical Diagnostics Inc, a U.S. diagnostics company that could be valued at more than ...

Raritan-based Ortho Clinical Diagnostics, a provider of in vitro diagnostics, announced its board of directors appointed Chris Smith as chief executive officer effective Sept. 9th. Smith will succeed ...

Carlyle Group is exploring a sale or initial public offering of Ortho-Clinical Diagnostics, which could be valued at more than $7 billion, including debt. A divestment of Ortho-Clinical Diagnostics ...